<DOC>
	<DOC>NCT00582166</DOC>
	<brief_summary>Subjects will receive the Zevalin(Ibritumomab Tiuxetan) therapeutic regimen; then rituximab consolidation and maintenance therapy every 3 months until disease progression</brief_summary>
	<brief_title>Zevalin(Ibritumomab Tiuxetan)+ Rituximab Maintenance</brief_title>
	<detailed_description>The objective of this study is to estimate the median progression -free survival for patients receiving this regimen, along with the rate of complete response at 6 months, toxicities associated with this regimen, and laboratory correlates. Subjects will receive the Zevalin(Ibritumomab Tiuxetan) therapeutic regimen; then rituximab consolidation and maintenance therapy every 3 months until disease progression.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Patients with biopsyproven nonhodgkins lymphoma of follicular grade 1, 2, or 3 Meeting FLIPI criteria for intermediate or high risk. No prior chemotherapy, radiotherapy or immunotherapy for lymphoma; Patients may not have known HIV infection, and must not be Hepatitis B Surface Antigen positive. May not be pregnant or breastfeeding, have documented CNS disease, GCSF or GMCSF within 2 weeks prior</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Zevalin, High Tumor Burden Indolent Non-Hodgkin's Lymphoma</keyword>
</DOC>